Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6854—Immunoglobulins
  • G01N33/686—Anti-idiotype
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Definitions

• This invention relates to assay methods for the quantitation of cellular receptors on peripheral blood cells and. more particularly, to the use of monoclonal labeled anti-idiotypic antibodies as ligand mimics for the quantitation of receptors.
• receptors may be broadly subdivided into two categories: (1) intracellular receptors, present in the cytoplasm or nucleus of the cell; and (2) surface receptors, present in the cell membrane. Although the two classes of receptors differ chemically, the principles of selective and specific ligand binding,apply equally to both.
• a number of pathological states are characterized by alterations in the properties of biospecific receptors, the most prevalent of these alterations being a change in apparent receptor level. Changes in apparent receptor level can arise from appearance or loss. change in numbers, binding constants, availability, etc. It is therefore often of interest to be able to quantitate the apparent number of receptors for a given ligand in a given tissue. In some cases, receptors can occur on peripheral blood cells (lymphocytes. erythrocytes, platelets, etc.) where they can be assayed without the need for biopsy. Table I lists a number of such receptors. the cell types on which they can be found and the disease states in which their apparent level is altered.
• Receptor immunoassays utilizing specific anti-receptor antibodies, provide an attractive alternative to the traditional method described above.
• Anti-receptor antibodies can be labeled conveniently with isotopic or non-isotopic labels, for example, enzymes and fluorophores.
• isotopic or non-isotopic labels for example, enzymes and fluorophores.
• the production of antibodies having the desired properties has been limited by the difficulty of obtaining receptors in sufficiently pure form to render them useful as immunogens.
• Receptors typically occur in extremely low concentrations, typically less than 0.01% of the total membrane protein, and are difficult to purify.
• Most of the presently available anti-receptor antibodies have been raised against receptors isolated from non-human sources. Typically.
• anti-receptor antibodies which mimic the ligand in its binding behavior vis a vis the receptor by preparing antibodies to idiotypic determinants on an anti-ligand antibody.
• idiotype or idiotypic determinant refers to the antigenic determinant(s) of an immunoglobulin (antibody) molecule which is (are) associated with the Fv region.
• Antibodies are composed of two heavy (H) chains and two light (L) chains, associated via one or more disulfide bonds. Each chain can be subdivided into a C-terminal constant region and an N-terminal variable (V) region. The V H and V L regions taken together make up the Fv region of an immunoglobulin.
• Antibodies which react with determinants in the Fv region are referred to as anti-idiotypic antibodies.
• idiotypic determinants are located in or very close to the ligand-binding site. In such cases. ligand can competitively inhibit the binding of anti-idiotypic antibody to idiotypic antibody (anti-ligand antibody). Such anti-idiotypic antibodies are said to be ligand-inhibitable, and they behave as ligand mimics.
• the antibodies described above are all polyclonal and are all too low in affinity for their respective receptors to be of any practical use in a diagnostic immunoassay.
• receptor assays which do not require radiolabeled ligand; do not require purified receptor: do not require biopsy specimens: and are rapid, sensitive, and potentially amenable to automation.
• the instant invention provides an improvement over existing methods for the assay of receptors on normally biopsied tissues. These existing methods comprise incubating tissues with radiolabelled biospecific receptor ligands.
• the improvement comprises:
• the amount of label bound to the cell is proportional to the apparent receptor level on the cell.
• the label can be an enzyme, fluorophore. chemilumine- scent material, bioluminiscent material, enzyme inhibitor, cofactor, as well as a radioisotope. Numerous other labeling substances are known in the patent and non-patent literature.
• the antibody can be directly labeled or can be indirectly labeled by use of a directly labeled heterologous antibody reactive with the F region of the anti-idiotypic antibody.
• the anti-idiotypic antibody can be coupled to one of two complementary molecules such as biotin or avidin and a conventional label (radioisotope, enzyme, fluorophore, etc.) can be coupled to the other molecule (avidin or biotin. respectively).
• a conventional label radioisotope, enzyme, fluorophore, etc.
• Antibodies can be prepared either by conventional immunization or by cell fusion techniques, the latter method yielding monoclonal or hybridoma antibodies.
• an animal is immunized with the ligand of interest emulsified in adjuvant and boosted at regular intervals.
• the serum is assayed for the presence of anti-ligand antibody by any convenient method, frequently RIA or ELISA. Once an acceptable titer of antibody is found, the animal can be bled and the antibodies purified from serum, or the animal (usually a mouse) sacrificed and its spleen removed aseptically for fusion.
• a single cell suspension is prepared and the immune spleen cells are fused using polyethylene glycol (PEG) with a hypoxanthine guanine phosphoribosyl transferase (HGPRT)-deficient plasmacytoma line.
• PEG polyethylene glycol
• HGPRT hypoxanthine guanine phosphoribosyl transferase
• aminopterin, and thymidine HAT
• the culture supernatant fluid is sampled and tested for antibody by any convenient means, frequently RIA or ELISA.
• Those cultures which contain antibody of interest are then cloned by limiting dilution or in soft agar, re-tested. and expanded.
• the clones of interest are then injected into syngeneic or congenic mice. If injected intravenously or subcutaneously, antibodies are then harvested from the serum. If injected intraperitoneally into pristane-primed animals. antibodies are harvested from ascites fluid.
• Ab l anti-ligand antibody
• Ab 2 anti-idiotypic antibodies
• Antibody purification techniques are well-known in the art. In general, the serum or ascites is precipitated with ammonium sulfate to yield an immunoglobulin (Ig) fraction and the resultant precipitate re-suspended in an aqueous medium for ion-exchange or gel filtration chromatography for isolation of the antibody class of interest. Chromatography on staphlyococcal protein A can also be used if the antibody activity resides in a protein A-binding subclass of IgG. Further purification can be achieved by chromatography on a ligand affinity column.
• Ig immunoglobulin
• Ab l is injected into animals to produce Ab2. Since it is desirable that Ab 2 have an affinity of at least 10 9 Mol -1 and be ligand-inhibitable, it is preferred that Ab 2 be a monoclonal antibody. Although in theory Ab 2 can be produced in any species, it is easier from a practical point of view to produce Ab 2 if Ab 2 is made in the same species used to make Ab l . While rat x rat. rat x mouse, human x human, and mouse x human hybridomas are known, they are in general more difficult to make and less stable than mouse x mouse hybridomas. Therefore, it is generally preferred that Ab 2 be made in a mouse and even more preferred that it be made in a syngeneic mouse to minimize the production of antibodies to non-idiotypic determinants.
• Ab 2 is screened for its ability to bind to receptor in a ligand-inhibitable manner. Once a suitable antibody has been identified, it is purified as described above and labeled.
• Ab 2 can be further screened for its ability to bind to the receptor with an association constant of at least about 10 9 Mal -1 by Scatchard analysis.
• labels are known in the art. Among the most widely used are enzymes such as B-galactosidase. horseradish peroxidase. and alkaline phosphatase. Where the label is an enzyme, it is desirable that it have a high turnover number, a readily available chromogenic or fluorogenic substrate, and appropriate functional groups for coupling to Ab 2 . In addition. it is useful if the enzyme is stable and not present in human serum. Suitable functional groups on the enzyme for coupling include amino, carboxyl. and sulfhydryl groups and carbohydrate moieties. The same functional groups can also be utilized on Ab 2 .
• Ab 2 In general, it is desirable to label Ab 2 as extensively as possible without loss of either antigen-binding or enzymatic activity. It is usually possible to attach as many as four horseradish peroxidase molecules per antibody, but probably only one B-galactosidase molecule because of its several- fold higher molecular weight.
• B-galactosidase has a free sulfhydryl group and horseradish peroxidase has carbohydrate moieties which can be utilized for coupling.
• conjugate Following labeling, it is usually desirable to purify the conjugate to remove unconjugated enzyme and antibody, as well as non-immunoreactive antibody. This can be accomplished by a combination of gel filtration and affinity chromatography steps.
• Ab 2 can be either divalent or monovalent.
• Techniques for the production of monovalent-antibody fragments are well-known in the art.
• Fab fragments can be made by cleaving IgG with papain and Fab' fragments can be made by the reduction and alkylation of F(ab') 2 fragments. which in turn are made by pepsin clevage of IgG.
• Peripheral blood cells can be isolated by known methods. The most commonly-employed method is probably density gradient centrifugation. For example. red blood cells can be separated from lymphocytes and platelets on a Ficoll-Hypaque gradient. Bovine serum albumin and colloidal silica gradients can also be employed. Platelets can be separated from lymphocytes by low speed centrifugation. Lymphocytes can be fiac- tionated into B and T cells on Percoll gradients.
• the assay of this invention can be used to quantify cellular receptors which occur either on the cell surface or in the cytoplasm.
• To measure cytoplasmic receptors it is first necessary to lyse the cells. Lysis with a non-ionic detergent such as Triton X-100 or Nonidet P-40 is usually preferred, but osmotic lysis is also possible.
• the assay of this invention for cellular associated receptors is carried out by incubating isolated peripheral blood cells with a labeled monoclonal anti-idiotypic antibody; washing the cells to remove unbound labeled antibody; and measuring the amount of label bound to the cell surface.
• the peripheral blood cells can be erythrocytes, lymphocytes, granulocytes, or platelets and can be isolated by any suitable method, most commonly density gradient centrifugation.
• the cells are washed with a buffered isotonic TMR solution or with medium. They are then counted either manually on a hemocytometer or automatically using, for example, a Coulter counter, and adjusted to the desired concentration. If necessary, cell viability can also be determined at this stage, usually by staining with a vital dye.
• Incubation times will typically range from five minutes to three hours, most often from thirty minutes to one hour.
• the temperature of incubation can range from 0°C to 45 °C , most often 37°C.
• the cells will usually be incubated in an isotonic solution, buffered to a pH between 4 and 10, more often between 6 and 8.
• the buffer can contain other substances, for example. 0.1 to 1.0% (by weight) BSA.
• preservatives or metabolic inhibitors for the dual purpose of preventing microbial contamination and preventing receptor modulation.
• the cells incubate the cells in a nutrient medium: this can be especially desirable if prolonged incubation times are to be used and cell viability at the time of assay is required.
• the type of medium used depends on the cells being assayed. Typically, RPMI-1640 and Dul- becco's modified essential medium (DMEM) are used.
• DMEM Dul- becco's modified essential medium
• the cells are washed with buffer or medium, usually the same buffer or medium in which the incubation was performed. Washing is usually accomplished by suspension in washing medium followed by centrifugation and aspiration of the supernatant fluid.
• the cells can be washed by filtration.
• the washed cells are then resuspended in a suitable buffer containing any necessary reagents for the detection of label.
• the label is an enzyme, a substrate and any necessary cofactors and cations for assay of the bound enzyme label will be included in the buffer.
• Enzyme activity can be measured photometrically or fluori- metrically as either the rate of change in absorbance (or transmission) at a suitable wavelength or as an end point determined after a fixed length of time.
• the temperature at which activity is determined can range from 0°C to 45°C. most often from 25°C to 37°C.
• the amount of enzyme activity (if label is an enzyme) can be related to the apparent receptor level either by comparison with a standard curve or by Scatchard analysis.
• FACS fluorescence-activated cell sorting analysis
• the receptor level on cells from a patient is compared to a reference which will be the receptor level on cells from normal individuals. Changes in receptor levels on a patient's cells, in comparison to reference values, will often be indicative of certain disease states including some of the diseases listed in Table 1. For example, a 66% decrease in the binding of glucagon to circulating mononuclear cells from patients with diabetes compared with non-diabetic controls has been reported. [Goldstein et al.. Endocrine Research Communication. Volume 2. 367 (1980)]
• the receptor level When the measured receptor level is to be used by a clinician to design a specific therapeutic regimen for a particular patient or to monitor the efficacy of such treatment, the receptor level will be compared to a reference which will be the receptor level on cells from the same individual prior to the initiation of therapy or the receptor level on cells from normal, untreated individuals. For example, measurement of the number of lymphocyte glucocorticoid receptors in non-Hodgkins lymphoma and in acute lym- phoblastic leukemia is useful in selecting those patients likely to benefit from glucocorticoid therapy. [ S hipman et al.. Blood, Volume 58, p. 11 9 8 (1 9 81)]
• the receptor level When the measured receptor level is to be used to monitor the physiological state of the cells, such as activation caused by mitogens, viruses or tumor- induced transformation, the receptor level will be compared to a reference which will be the receptor level on unactivated cells obtained from normal individuals. For example, resting T-lymphocytes possess few glucagon receptors. However, following activation of such cells with T-cell specific mitogens, the numbers of such receptors increases dramatically, indicating that the glucagon receptor is a marker of activated T-lymphocytes [Bhathena et al., Endocrinology. Volume 111, p. 684 (1982)]
• Glucagon was covalently linked to the carrier keyhole limpet hemocyanin (KLH) using carbodiimide.
• KLH carrier keyhole limpet hemocyanin
• 0.5 mg of glucagon and 2.5 mg of KLH were dissolved in 1.5 mL distilled H 2 0 and titrated with 1 N NaOH until complete dissolution was achieved.
• 0.5 mL of an aqueous solution of 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide (EDAC. 3.5 mg/mL) was added and the solution incubated at room temperature for 18 hours.
• 2 mL of 0.05 M hydroxyamine hydrochloride was added and the solution incubated an additional 5 hours at room temperature.
• the resultant conjugate having a ratio of glucagon to KLH of approximately 8-10:1, was emulsified in an equal volume of complete Freund's adjuvant (CFA) and 25 ⁇ g was injected into the footpads of Balb/c mice. Two weeks later the mice were boosted intraperitoneally with 12.5 ⁇ g of the conjugate emulsified in incomplete Freund's adjuvant (IFA). Thereafter the animals were boosted monthly and their sera assayed for the presence of antibody 7 days after each boost, as described below.
• CFA complete Freund's adjuvant
• Antibody to glucagon was detected using an enzyme-linked immunosorbent assay (ELISA).
• Glucagon was covalently coupled to bovine serum albumin (BSA) using carbodiimide, as described above. 10 ⁇ g of the glucagon/BSA conjugate (ratio of glucagon to BSA approximately 8-10:1). in 100 ⁇ L of phosphate buffered saline. pH 7.4 (PBS) was added to individual wells of a 96-well polyvinyl chloride microtiter plate and allowed to incubate for 1 hour at room temperature. The plates were flicked to remove excess conjugate solution and 50 ⁇ L of the test serum, diluted from 10 -1 to 10-6 in PBS/0.1% BSA.
• PBS phosphate buffered saline. pH 7.4
• An Ig fraction was prepared from whole serum by precipitation with 45% saturated ammonium sulfate. The resultant precipitate was redissolved in H 2 0 and concentrated by ultra-filtration, then dialyzed against PBS, pH 7.4.
• a glucagon affinity column was prepared by coupling the hormone to CNBr-activated Sepharose 4B following the procedure recommended by the manufacturer (Pharmacia Fine Chemicals). The ratio of glucagon to Sepharose 4B was 5 mg/g wet weight.
• the Ig fraction obtained above was passed over the column and eluted with 0.23 M glycine buffer, pH 3.4. 2 M Tris.
• mice 100 ⁇ g of the Ig fraction prepared above or 25 ⁇ g of the affinity-purified material was emulsified in CFA and injected into the footpads of Balb/c mice. The animals were boosted intraperitoneally at monthly intervals, using antibody emulsified in IFA. After three months, the mice were bled and the serum tested for the presence of anti-idiotypic antibodies reactive with the glucagon receptor, as described in (E) below.
• Rat liver plasma membranes rich in glucagon receptors were prepared by mincing livers from Sprague-Dawley rats. The liver suspension was adjusted to a sucrose concentration of 43.3%: 25 mL of this suspension was placed in centrifuge tubes, overlaid with 10 mL of 42.3% sucrose, and centrifuged in an SW 28 rotor (Beckman Instruments. Spinco Division) for 2 hours at 27.000 rpm. Purified membranes floated to the top of the tube where they were recovered. Membrane mass was determined by the Lowry method. 25 ⁇ g of membrane protein, in 1 mM sodium bicarbonate.
• mice producing sera which responded positively in the assay described in (E) above were given a final boost and sacrificed 3 days later. Their spleens were removed aseptically and fused with cells of the F/O murine plasmacytoma line. Any number of murine plasmacytoma lines may be used, including SP2/0-Agl4 and P3x63-Ag8.653, which are on deposit at the American Type Culture Collection identified by numbers CRL-1581 and CRL-1580, respectively. The ratio of spleen cells to plasmacytoma cells used in the fusion was 2:1, polyethylene glycol 4000 was the fusing agent.
• Cells were plated at a density of 2 x 10 5 spleen cells per well in 96 well microtiter plates containing HAT (hypoxanthine. aminopterin, thymidine) selective medium. Cells were fed with fresh HAT medium on a weekly basis for the first two weeks and thereafter with HT (no aminopterin) medium. After 2 to 4 weeks. the supernatant fluids from wells displaying cell growth were tested for the presence of antibodies reactive with the glucagon receptor using the assay described in (E) above. Cells producing the antibody were cloned by limiting dilution and expanded in culture.
• HAT hypoxanthine. aminopterin, thymidine
• Antibody is isolated from culture supernatants by precipitation with ammonium sulfate, followed by DEAE-cellulose chromatography. Specificity is verified by the ELISA procedure described in (B) above using the affinity-purified idiotype from (C) as antigen. Class, subclass, isoelectric point, and affinity are determined for each antibody. Class and subclass are determined by immunodiffusion in an agar gel. using commercially available class- and subclass- specific antisera. Isoelectric point is determined by isoelectric focusing in polyacrylamide gel. Affinity is determined by Scatchard analysis.
• HRP horseradish peroxidase
• the dialyzed solution containing activated HRP is added to 2 mg of anti-(anti-glucagon) antibody. After 3 hours incubation at room temperature. 5 mg of sodium borohydride is added, and the incubation is continued for 3 hours at 4°C. The mixture is then dialyzed exhaustively against PBS at 4°C.
• the conjugate solution is then fractionated on Ultrogel AcA 44 (LKB: 1.6 x 95 cm column; 4% polyacrylamide/14% agarose gel having a 200.000 Dalton exclusion limit) to separate labeled from unlabeled antibody, the former eluting in the void volume.
• the column fractions containing peak enzyme activity are pooled and concentrated to 2 mL by pressure filtration (P M -3 0 Amicon membrane), then purified by affinity chromatography on an anti-glucagon column, as follows.
• the conjugate solution is passed through an anti-glucagon IgG affinity column (1 cm x 7 cm), followed by 100 mL of PBS.
• the affinity column is prepared by coupling affinity-purified antibody from (C) above to CNBr-activated Sepharose 4B at a ratio of 1 mg IgG per 1 mL wet gel.
• the bound conjugate is then eluted with 50 mL of 10 mM glucagon in PBS. This eluate represents the final reagent and is dialyzed sequentially six times against 4 L of PBS at 4°C.
• F ab' fragments are prepared from affinity purified antibodies via pepsin digestion. Twenty mL of affinity-purified anti-(anti-glucagon) antibodies are concentrated to 2 mL on an Amicon stirred-cell appa- ra tus (PM-30 membrane). The final protein concentration is adjusted to 10 mg/mL. The sample is dialyzed against 1000 mL of 0.1 M sodium acetate, pH 4.5, for 4 hours at 4°C. After dialysis. 20 ⁇ L of a 10 mg/mL solution of pepsin, dissolved in the same sodium acetate buffer, is added and the temperature raised to 37°C for 20 hours.
• the sample is clarified by a brief centrifugation and then chromatographed on a Sephadex G-150 (cross-linked. beaded dextran having 150,000 dalton exclusive limit) column (1.5 cm x 90 cm) equilibrated in 0.015 M sodium phosphate (pH 7.4), 0.15 M NaCl (phosphate buffered saline).
• the column fractions containing the (Fab') 2 fragments, identified by gel electrophoresis, are pooled (19.2 mL) and then concentrated to 2.0 mL by pressure filtration (PM-30 Amicon membrane).
• the (Fab') 2 fragments are reduced to their corresponding Fab' fragments by adding 40 ⁇ L of a 1 M dithiothreitol solution. The reduction is performed at 25°C for 90 min under argon. The Fab' fragments are then reacted with 14.8 mg of iodoacetamide at 25°C for 2 hours under argon. Reaction products are removed by three sequential dialyses against 4 liters of phosphate buffered saline at 4 °C.
• the Fab' fragments so produced are then reacted with a 20-fold molar excess of MBS (m-maleimidobenzoic acid N-hydroxy-succinimide ester). Eighty-five microliters of a 79 mM solution of MBS in tetrahydrofuran are added to the 2 mL solution of Fab' fragments and reacted for 1 hour at 25°C under argon. The mixture is desalted on a Sephadex G-25 (cross-linked, beaded dextran having 5000 dalton exclusion limit) column (1.5 cm x 40 cm) in phosphate buffered saline.
• MBS m-maleimidobenzoic acid N-hydroxy-succinimide ester
• the derivatized Fab' fragments which eluted in the void volume are pooled and combined with 2 mL of B-galactosidase at 12 mg/mL in phosphate buffered saline at 4°C. After 16 hours, this solution is concentrated to 2 mL on a Amicon PM-30 pressure filtration stirred-cell followed by column chromatography on Sepharose 4 B-CL (cross-linked, macroporous agarose in bead form having 1-5 x 10 6 dalton exclusion limit in a 1.5 cm x 90 cm column).
• the Fab'-B-galactosidase conjugate is eluted with the free B-galactosidase.
• the entire peak of enzyme activity is pooled and subsequently immunopurified on an anti-glucagon affinity column.
• the procedure for immunopurification is as follows: Pooled column fractions from the Sepharose 4B-CL column are eluted through the anti-glucagon affinity column (1.0 cm x 7.0 cm), followed by 100 mL of phosphate buffered saline. The Fab'-B-galactosidase conjugate is then eluted with 50 mL of 10 mM glucagon in phosphate buffered saline. This eluate represents the final reagent and is dialyzed sequentially six times against 4 L of phosphate buffered saline at 4°C.
• Blood obtained from patients or normal volunteers by venipuncture is collected in heparin-containing tubes. Separation of the cellular components of whole blood is accomplished by layering the blood sample, diluted in an equal volume of balanced salt solution (BSS). onto FICOLL-PAQUE (Pharmacia Fine Chemicals, a copolymer of sucrose and epichlorhydrin which has a weight average molecular weight between 300,000 and 500.000) and centrifuging at 400 x g for 30 minutes at 18-20°C. Erythrocytes are collected from the bottom of the tube where they sediment, while lymphocytes, monocytes and platelets, remain at the sample/FICOLL-PAQUE interface.
• BSS balanced salt solution
• the cells recovered from the interface are resuspended in BSS and centrifuged for 3 minutes at 2900 x g.
• the platelets are collected from the top while the heavier monocytes and lymphocytes pellet to the bottom.
• the pellet is re- suspended in BSS and the monocytes are separated by adherence to plastic petri dishes for 30 minutes at 25°C. Lymphocytes do not adhere to the plastic and are pipetted off while the adherent cells (monocytes) are recovered from the petri dish by tapping the plate vigorously and rinsing with BSS.
• B and T lymphocytes Separation of B and T lymphocytes is accomplished by layering the lympho- ctye fraction over a discontinuous gradient of Percoll (Pharmacia Fine Chemicals, colloidal silica with non- dialyzable polyvinylpyrrolidone coating having a density of 1.130 gm/mL) and centrifuging for 10 minutes at 3000 rpm.
• B cells band at a lighter density than T cells and are collected at the interface between the densities 1.052 and 1.063 gm/mL.
• T-lymphocytes 5 x 10 6 T-lymphocytes, isolated as described above, are suspended in 75 ⁇ L of BSS. 25 uL of a 1 mg/mL solution of B-galactosidase labeled Fab' fragment of a monoclonal anti-idiotypic antibody reactive with the glucagon receptor, prepared as described above, hereinafter referred to as Ab 2 , is added and the mixture is incubated for 1 hour at 37°C. The cells are pelleted by centrifugation and washed 3 times with BSS. After the last wash. the cells are resuspended in PBS, pH 7.4, containing 100 mM 2-mercaptoethanol and 3 mM PNPG.
• the cells After a one-hour incubation at 37°C, the cells are again pelleted by centrifugation. The supernatant is withdrawn and the absorbance of the supernatant fluid measured at 414 nm. The absorbance is directly proportional to the amount of labeled Ab 2 bound to the cells. This value is compared to a standard curve relating absorbance to apparent receptor density.
• the above described assay is a single point assay in that only one dilution of antibody is used.
• Single point assays will often be useful when comparing receptor levels on a patient's cells with a reference value, especially when there are large differences between the two values.
• Such a multi-point assay allows one to do a Scatchard analysis of the data. Scatchard analysis of glucagon receptors on T-lymphocytes is performed by incubating a series of tubes each containing a standard amount of labeled Ab 2 and 5X10 T-lymphocytes with a range of concentrations of unlabeled Ab 2 for 60 minutes at 37°C.
• the level of receptors on a patient's cells obtained by single point assay or the affinity and receptor numbers obtained by Scatchard analysis is compared with reference values obtained by performing similar measurements on cells from normal individuals. Statistically significant differences in the values may be indicative of a specific disease. For glucagon, a significant decrease in glucagon receptor level on a patient's mononuclear cells, in comparison to the reference, is suggestive of diabetes.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Biotechnology (AREA)
• Analytical Chemistry (AREA)
• Cell Biology (AREA)
• Pathology (AREA)
• Food Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• Physics & Mathematics (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• General Physics & Mathematics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=24070739

Family Applications (1)

Country Status (2)

Cited By (7)

Citations (1)

• 1984
  • 1984-08-01 EP EP19840109091 patent/EP0133540A1/fr not_active Withdrawn
  • 1984-08-02 JP JP16164684A patent/JPS6070360A/ja active Pending

Patent Citations (1)

Also Published As

Similar Documents

Legal Events